BioLineRx Ltd. (BLRX)
NASDAQ: BLRX
· Real-Time Price · USD
3.75
-0.02 (-0.53%)
At close: Aug 15, 2025, 3:59 PM
3.77
0.53%
After-hours: Aug 15, 2025, 07:16 PM EDT
BioLineRx Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 255K | 11.75M | 4.94M | 5.39M | 6.86M | 4.8M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 34K | 6.09M | 822K | 897K | 1.46M | 3.69M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 221K | 5.66M | 4.12M | 4.5M | 5.4M | 1.11M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -2.39M | -4.43M | -5.39M | -5.77M | -4.82M | -18.57M | -12.36M | -9.91M | -8.86M | -8.4M | -7.08M | -7.6M | -6.08M | -6.6M | -6.22M | -6.51M | -5.45M |
Interest Income | 294K | 286K | 434K | 535K | 565K | 718K | 312K | 440K | 537K | 438K | 109K | 80K | 67K | 260K | 52K | 130K | 117K |
Pretax Income | 5.13M | -3.19M | -5.82M | 484K | -696K | -13.88M | -16.02M | -18.55M | -12.16M | -5.73M | -6.85M | -7.44M | -4.93M | -4.3M | -5.72M | -6.84M | -10.19M |
Net Income | 5.13M | -3.19M | -5.82M | 484K | -696K | -13.88M | -16.02M | -18.55M | -12.16M | -5.73M | -6.85M | -7.44M | -4.93M | -4.3M | -5.72M | -6.84M | -10.19M |
Selling & General & Admin | 989K | 5.83M | 6.94M | 8.04M | 7.73M | 9.87M | 9.63M | 6.91M | 5.17M | 4.93M | 2.71M | 2.21M | 1.64M | 1.43M | 1.29M | 1.37M | 1.17M |
Research & Development | 1.62M | 1.86M | 2.56M | 2.23M | 2.49M | 3.1M | 2.73M | 3.01M | 3.68M | 3.43M | 4.37M | 5.39M | 4.43M | 5.13M | 4.92M | 5.14M | 4.28M |
Other Expenses | n/a | 2.4M | n/a | n/a | n/a | 1K | n/a | n/a | n/a | 39K | n/a | n/a | n/a | 42K | n/a | n/a | n/a |
Operating Expenses | 2.61M | 10.09M | 9.51M | 10.27M | 10.22M | 12.97M | 12.36M | 9.91M | 8.86M | 8.4M | 7.08M | 7.6M | 6.08M | 6.6M | 6.22M | 6.51M | 5.45M |
Interest Expense | 420K | 4.43M | 1.63M | 2.08M | 929K | -932K | 837K | 1.34M | 927K | 1.33M | 267K | 379K | 186K | 204K | 261K | 242K | 299K |
Selling & Marketing Expenses | n/a | -8.23M | 5.55M | 6.42M | 6.34M | -3.02M | 8.13M | 5.6M | 3.87M | 3.35M | 1.32M | 1.16M | 637K | 272K | 247K | 330K | 154K |
Cost & Expenses | 2.65M | 16.18M | 10.33M | 11.17M | 11.68M | 16.66M | 12.36M | 9.91M | 8.86M | 8.4M | 7.08M | 7.6M | 6.08M | 6.6M | 6.22M | 6.51M | 5.45M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 79.86M | 79.86M | 79.86M | 79.84M | 72.44M | 71.9M | 61.94M | 61.53M | 61.53M | 51.6M | 49.38M | 47.69M | 47.68M | 44.2M | 47.23M | 44.61M | 37.3M |
Shares Outstanding (Diluted) | 79.86M | 79.86M | 79.86M | 79.84M | 72.44M | 71.89M | 61.94M | 61.53M | 61.53M | 51.6M | 49.38M | 47.69M | 47.68M | 44.2M | 47.23M | 44.61M | 37.3M |
EPS (Basic) | 0.06 | -0.04 | -0.07 | 0.01 | -0.01 | -0.19 | -0.26 | -0.3 | -0.19 | -0.06 | -0.13 | -0.15 | -0.08 | -0.1 | -0.12 | -0.15 | -0.27 |
EPS (Diluted) | 0.06 | -0.04 | -0.07 | 0.01 | -0.01 | -0.19 | -0.26 | -0.3 | -0.19 | -0.06 | -0.13 | -0.15 | -0.08 | -0.1 | -0.12 | -0.15 | -0.27 |
EBITDA | 5.71M | 3.1M | -3.36M | 3.04M | 1.13M | -14.14M | -14.96M | -17.01M | -10.98M | -4.59M | -6.43M | -6.92M | -4.57M | -3.95M | -5.29M | -6.42M | -9.71M |
EBIT | 5.55M | 1.25M | -4.2M | 2.57M | 233K | -14.84M | -15.19M | -17.21M | -11.23M | -4.78M | -6.58M | -7.06M | -4.74M | -4.12M | -5.46M | -6.6M | -9.89M |
Depreciation & Amortization | 165K | 1.85M | 840K | 476K | 897K | 706K | 221K | 198K | 259K | 187K | 153K | 141K | 173K | 174K | 167K | 180K | 182K |